GoAI
Get started
Azitra, Inc. logo

Azitra, Inc.

AZTR

AMEXHealthcareBiotechnology

Open in GoAI

Previous close

$0.1328

+$0.0061 · +4.81%

Aug 21, 4:00 PM ET

AZTR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

41

Fair Value

Momentum

17

Strong Down

Sentiment

59

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Francisco D. Salva
Listed since
Jun 20, 2023
Employees
13

Market position

Day range

Current $0.1328

52-week range

Current $0.1328

Open
$0.135
Previous close
$0.1267
Volume
1.95M
0.18× average
Average volume
11.12M
Average daily volume
Market cap
1.43M USD
Beta
-1.18
Market reference 1
50-day average
$0.1516
-12.41% below average
200-day average
$0.2314
-42.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-355.49K USD
EV / EBITDA
0.03×
Earnings yield
-848.91%
Free cash flow yield
-884.16%

Profitability & efficiency

Return on equity
-288.21%
Return on assets
-218.00%
Return on invested capital
-259.67%

Financial health

Current ratio
2.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends14757%-43871%-102498%-161125%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2021: -8383.14%Operating margin, FY2022: -3328.73%Operating margin, FY2023: -1086.09%Operating margin, FY2024: -146468.53%Net margin, FY2021: -8126.98%Net margin, FY2022: -3760.69%Net margin, FY2023: -1644.87%Net margin, FY2024: -119566.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2021 -8383.14%. Operating margin FY2022 -3328.73%. Operating margin FY2023 -1086.09%. Operating margin FY2024 -146468.53%. Net margin FY2021 -8126.98%. Net margin FY2022 -3760.69%. Net margin FY2023 -1644.87%. Net margin FY2024 -119566.56%.

Income trends

Revenue

7.5K USD-98.91%

Operating income

−10.97M USD+0.17%

Net income

−10.96M USD-22.17%
Income trends across reported periods1.88M USD−2.9M USD−7.69M USD−12.48M USDRevenue, FY2021: 110K USDRevenue, FY2022: 284K USDRevenue, FY2023: 686K USDRevenue, FY2024: 7.5K USDOperating income, FY2021: −9.22M USDOperating income, FY2022: −9.45M USDOperating income, FY2023: −7.45M USDOperating income, FY2024: −10.99M USDOperating income, FY2025: −10.97M USDNet income, FY2021: −8.94M USDNet income, FY2022: −10.68M USDNet income, FY2023: −11.28M USDNet income, FY2024: −8.97M USDNet income, FY2025: −10.96M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 110K USD. Revenue FY2022 284K USD. Revenue FY2023 686K USD. Revenue FY2024 7.5K USD. Operating income FY2021 −9.22M USD. Operating income FY2022 −9.45M USD. Operating income FY2023 −7.45M USD. Operating income FY2024 −10.99M USD. Operating income FY2025 −10.97M USD. Net income FY2021 −8.94M USD. Net income FY2022 −10.68M USD. Net income FY2023 −11.28M USD. Net income FY2024 −8.97M USD. Net income FY2025 −10.96M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—7.5K USD686K USD284K USD110K USD
Gross profit—7.5K USD686K USD284K USD110K USD
Research and development4.84M USD4.72M USD3.64M USD6.1M USD5.38M USD
Selling, general, and administrative6.13M USD6.27M USD4.49M USD3.64M USD3.95M USD
Operating expenses10.97M USD10.99M USD8.14M USD9.74M USD9.33M USD
Interest income70.21K USD122.55K USD1.58K USD4.82K USD8.76K USD
Interest expense7.59K USD12.16K USD167.73K USD251.89K USD66.97K USD
Depreciation and amortization453.14K USD448.24K USD425.55K USD405.98K USD84.77K USD
Operating income−10.97M USD−10.99M USD−7.45M USD−9.45M USD−9.22M USD
Net income−10.96M USD−8.97M USD−11.28M USD−10.68M USD−8.94M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution
Maxim GroupmaintainBuy

Corporate actions

Corporate action history

Stock split

Effective Aug 21, 2025

6.66:1

Stock split

Effective Jul 1, 2024

1:30

Continue in GoAI

Research AZTR

research.disclaimer